Evidence map›Paper›PMID 41477337›Full record

ArticleActa pharmaceutica Sinica. B2025

Injectable hydrogel-mediated co-delivery of oncolytic adenovirus and melphalan for retinoblastoma control and vision preservation.

Guoqing Wang, Kai Wu, Zongliang Zhang, Yongdong Chen, Yanfang Li, Xiaoshuang Jiang, Licong Liang, Yiliu Yang, Hongsong Fan, Jing Sun and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Guoqing WangDepartment of Ophthalmology, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
Kai WuNational Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, China.
Zongliang ZhangState Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, Frontiers Medical Center Tianfu Jincheng Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.
Yongdong ChenState Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, Frontiers Medical Center Tianfu Jincheng Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.
Yanfang LiState Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, Frontiers Medical Center Tianfu Jincheng Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.
Xiaoshuang JiangDepartment of Ophthalmology, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
Licong LiangDepartment of Ophthalmology, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
Yiliu YangDepartment of Ophthalmology, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
Hongsong FanNational Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, China.
Jing SunNational Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, China.
Aiping TongState Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, Frontiers Medical Center Tianfu Jincheng Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.
Fang LuDepartment of Ophthalmology, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoblastoma (RB) is the most common primary ocular malignancy in children, arising from the developing retina. While higher doses of local chemotherapy have improved tumor control, concerns regarding retinal toxicity and the development of chemoresistance remain significant. Oncolytic adenovirus (OA) presents a promising therapeutic approach for RB, but rapid clearance often limits its therapeutic effects. In this study, we engineered a genetically modified OA derived from human adenovirus 5 (Ad5), designed to selectively target and lyse RB cells. The combination of OA with low-dose melphalan demonstrates an enhanced antitumor effect, while minimizing retinal toxicity.

Indexed as

Combination therapyCyclodextrinInjectable hydrogelIntravitreal deliveryMelphalanOncolytic adenovirusRetinoblastomaViral therapy

Identifiers

PMID41477337
PMCPMC12750353

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.